S. Ahn

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.

H. Goldschmidt, K. Rippe, R. Sankowski, 2023, Cancer cell.

Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma

P. Neri, N. Leblay, S. Ahn, 2021, HemaSphere.

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

P. Neri, F. Maura, O. Landgren, 2022, Blood.

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

A. Rosenwald, J. Keats, A. Krishnan, 2023, Nature Medicine.

ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma

J. Keats, S. Lonial, B. Barwick, 2023, Blood cancer discovery.

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

F. Maura, N. Bahlis, B. Diamond, 2023, Blood.